About Sunesis Pharmaceuticals (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500
Debt
Debt-to-Equity RatioN/A
Current Ratio2.60%
Quick Ratio2.60%
Price-To-Earnings
Trailing P/E Ratio-1.95
Forward P/E Ratio-2.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$670,000.00
Price / Sales143.64
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book140.00
Profitability
EPS (Most Recent Fiscal Year)($1.45)
Net Income$-35,450,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-128.72%
Miscellaneous
Employees34
Outstanding Shares34,370,000
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals (NASDAQ:SNSS) announced its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.08. View Sunesis Pharmaceuticals' Earnings History.
What price target have analysts set for SNSS?
5 equities research analysts have issued 12-month target prices for Sunesis Pharmaceuticals' shares. Their forecasts range from $2.48 to $7.00. On average, they anticipate Sunesis Pharmaceuticals' stock price to reach $4.4933 in the next twelve months. View Analyst Ratings for Sunesis Pharmaceuticals.
What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (3/14/2018)
- 2. Cantor Fitzgerald analysts commented, "SNS-062 Data Now 3Q18. SNSS disclosed that it now expects to complete the Phase Ib trial of SNS-062 in fall 2018, which we interpret as early 4Q18, though it could be late 3Q18. The second dose cohort (50 mg) has not yet completed, but since a Phase Ia in healthy volunteers was run, our expectation has been that it would not take many doses to identify the Phase II dose (RP2D). While the reasons for the delay (rapidly progressing patient, non-drug related AE) are understandable, we think the disclosure could cause the shares to pull back." (3/8/2018)
- 3. Cowen Inc analysts commented, "Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of." (11/2/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Marinus Pharmaceuticals (MRNS), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Scpharmaceuticals (SCPH), Teligent (TLGT), Protagonist Therapeutics (PTGX), Zafgen (ZFGN), Evolus (EOLS), Spero Therapeutics (SPRO), Spring Bank Pharmaceuticals (SBPH), Avid Bioservices (CDMO), Kamada (KMDA), Proteostasis Therapeutics (PTI), Intec Pharma (NTEC), XBiotech (XBIT), Immune Design (IMDZ), NewLink Genetics (NLNK) and Tetraphase Pharmaceuticals (TTPH).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Mr. Dayton Misfeldt, Interim CEO & Director (Age 44)
- Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 55)
- Mr. William P. Quinn, CFO and Sr. VP of Fin. & Corp. Devel.
- Mr. Gene C. Jamieson, VP of Technical Operations
- Dr. Judith A. Fox Ph.D., Chief Scientific Officer
Has Sunesis Pharmaceuticals been receiving favorable news coverage?
News articles about SNSS stock have been trending positive recently, Accern reports. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a coverage optimism score of 0.25 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 44.99 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Sunesis Pharmaceuticals?
Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of SNSS stock can currently be purchased for approximately $2.80.
How big of a company is Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals has a market capitalization of $97.27 million and generates $670,000.00 in revenue each year. The biopharmaceutical company earns $-35,450,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Sunesis Pharmaceuticals employs 34 workers across the globe.
How can I contact Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]
MarketBeat Community Rating for Sunesis Pharmaceuticals (SNSS)
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sunesis Pharmaceuticals (NASDAQ:SNSS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 53.00%
Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/6/2017 | Mpm Oncology Impact Management | Major Shareholder | Buy | 81,500 | $2.77 | $225,755.00 | |  |
| 11/2/2017 | Mpm Oncology Impact Management | Major Shareholder | Buy | 25,300 | $2.59 | $65,527.00 | | |
| 10/27/2017 | Dayton Misfeldt | Director | Buy | 400,000 | $2.00 | $800,000.00 | | |
| 12/9/2016 | Geoffrey M Parker | Director | Buy | 3,740 | $3.87 | $14,473.80 | 65,151 | |
| 5/26/2016 | Geoffrey M Parker | Director | Buy | 9,500 | $0.47 | $4,465.00 | 62,005 | |
| 5/25/2016 | Geoffrey M Parker | Director | Buy | 52,505 | $0.47 | $24,677.35 | 30,000 | |
| 12/21/2015 | Dayton Misfeldt | Director | Buy | 1,750,000 | $0.84 | $1,470,000.00 | | |
| 8/25/2015 | Daniel N Swisher Jr | CEO | Buy | 12,216 | $1.01 | $12,338.16 | 179,510 | |
| 8/24/2015 | Daniel N Swisher Jr | CEO | Buy | 12,784 | $1.01 | $12,911.84 | 179,510 | |
| 8/29/2014 | Forest Baskett | Major Shareholder | Sell | 266,700 | $7.97 | $2,125,599.00 | | |
| 8/28/2014 | Bay City Capital Llc | Major Shareholder | Sell | 300,700 | $7.98 | $2,399,586.00 | | |
| 8/28/2014 | Dayton Misfeldt | Director | Sell | 200,000 | $7.89 | $1,578,000.00 | | |
| 8/27/2014 | Adam R Craig | CMO | Sell | 2,554 | $8.00 | $20,432.00 | | |
| 8/27/2014 | Daniel N Swisher Jr | CEO | Sell | 5,000 | $8.00 | $40,000.00 | | |
| 8/27/2014 | Dayton Misfeldt | Director | Sell | 100,700 | $8.16 | $821,712.00 | | |
| 8/27/2014 | Eric Bjerkholt | CFO | Sell | 10,000 | $8.00 | $80,000.00 | | |
| 8/27/2014 | Krishna Kittu Kolluri | Major Shareholder | Sell | 108,300 | $8.17 | $884,811.00 | | |
| 8/12/2014 | Dayton Misfeldt | Director | Sell | 743,700 | $6.64 | $4,938,168.00 | | |
| 8/12/2014 | Equity Opportunities Fu Growth | Major Shareholder | Sell | 710,540 | $6.63 | $4,710,880.20 | | |
(Data available from 1/1/2013 forward)
Sunesis Pharmaceuticals (NASDAQ SNSS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Sunesis Pharmaceuticals (SNSS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 20 at 8:50 AM |
| Zacks Investment Research Lowers Sunesis Pharmaceuticals (SNSS) to Sell
www.americanbankingnews.com - April 19 at 2:58 PM |
 | Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock?
www.zacks.com - April 9 at 8:56 AM |
| Brokerages Expect Sunesis Pharmaceuticals (SNSS) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 6 at 9:22 PM |
 | Edited Transcript of SNSS earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - April 1 at 8:47 AM |
 | Sunesis Pharmaceuticals (SNSS) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 28 at 4:58 PM |
| Sunesis Pharmaceuticals (SNSS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 26 at 8:04 AM |
| Sunesis Pharmaceuticals (SNSS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 10:56 AM |
| Sunesis Pharmaceuticals (SNSS) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - March 20 at 9:08 PM |
| Sunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - March 14 at 5:24 PM |
 | Sunesis Pharmaceuticals to Present at Upcoming Investor Conferences
feeds.benzinga.com - March 14 at 4:55 PM |
| Research Analysts Issue Forecasts for Sunesis Pharmaceuticals, Inc.'s FY2018 Earnings (SNSS)
www.americanbankingnews.com - March 14 at 9:50 AM |
 | Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 9:20 AM |
| Sunesis Offers A Great Buying Opportunity After Dip Due To Delay Of Cancer Data - Seeking Alpha
seekingalpha.com - March 14 at 9:20 AM |
| Sunesis Pharmaceuticals (SNSS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 13 at 6:55 PM |
| Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 13 at 8:57 AM |
| Sunesis Pharmaceuticals (SNSS) vs. Prosensa (RNA) Head-To-Head Review
www.americanbankingnews.com - March 13 at 1:18 AM |
| Sunesis Pharmaceuticals, Inc. to Post FY2021 Earnings of ($0.42) Per Share, Oppenheimer Forecasts (SNSS)
www.americanbankingnews.com - March 12 at 9:40 AM |
| Sunesis Pharmaceuticals (SNSS) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 9 at 6:35 PM |
| Cantor Fitzgerald Reaffirms "Hold" Rating for Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - March 9 at 12:10 AM |
| Sunesis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 6:08 PM |
| Sunesis Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - March 8 at 6:08 PM |
| Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 8 at 6:08 PM |
| Are Earnings Prospects Improving For Loss-Making Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS)?
finance.yahoo.com - March 7 at 8:52 AM |
| Sunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:43 AM |
| BIO-TECHNE (TECH) vs. Sunesis Pharmaceuticals (SNSS) Critical Comparison
www.americanbankingnews.com - March 5 at 11:36 AM |
| Sunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 4 at 9:52 AM |
| -$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - March 3 at 5:24 PM |
| Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 8:42 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 1 at 12:10 PM |
| Sunesis Pharmaceuticals (SNSS) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:58 AM |
| Investors Buy High Volume of Sunesis Pharmaceuticals Call Options (SNSS)
www.americanbankingnews.com - February 23 at 8:26 AM |
| Sunesis Pharmaceuticals (SNSS) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 15 at 2:08 PM |
| Sunesis Pharmaceuticals (SNSS) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 2:16 PM |
| Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
finance.yahoo.com - February 8 at 8:29 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 4 at 11:14 AM |
| Reviewing Fibrocell Science (FCSC) and Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - January 15 at 5:10 PM |
| Sunesis Pharmaceuticals (SNSS) and PRA Health Sciences (PRAH) Head to Head Contrast
www.americanbankingnews.com - January 14 at 3:58 AM |
| Financial Survey: WuXi PharmaTech (Cayman) (WX) versus Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - January 13 at 11:34 PM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - January 12 at 3:14 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 10 at 8:18 AM |
 | Mid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike Higher
www.nasdaq.com - January 4 at 3:27 PM |
| Zacks: Brokerages Expect Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - December 26 at 4:07 PM |
| -$0.25 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - December 26 at 4:07 PM |
| Reviewing Sunesis Pharmaceuticals (SNSS) and Synageva Biopharma (GEVA)
www.americanbankingnews.com - December 24 at 3:22 AM |
| Stocks to watch next week - Apple Inc. (NASDAQ:AAPL) | Seeking ... - Seeking Alpha
seekingalpha.com - December 23 at 9:13 PM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 16 at 8:46 AM |
| Sunesis Pharmaceuticals (SNSS) Now Covered by Oppenheimer
www.americanbankingnews.com - December 14 at 3:26 PM |
 | Pre-Open Movers 12/11: (BLUE) (BPMC) (SNSS) Higher; (SYRS) (ONCE) (GBT) Lower (more...)
www.streetinsider.com - December 13 at 3:28 PM |
| ARGX Soars, SNSS Catches Eyes, BPMC, BLUE Turn Heads, FDA Nod For SNNA
www.nasdaq.com - December 12 at 3:27 PM |
Sunesis Pharmaceuticals (NASDAQ:SNSS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sunesis Pharmaceuticals (NASDAQ:SNSS) Income Statement, Balance Sheet and Cash Flow Statement
Sunesis Pharmaceuticals (NASDAQ SNSS) Stock Chart for Monday, April, 23, 2018
Loading chart…
